Navigation Links
New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes

This in turn, leads to slowing or abortion of the translation process and subsequent degradation of the mRNA.4 When the problem of codon bias causes frameshifts, codon skipping, or misincorporations, it may escape detection. More commonly, manifestations of codon bias include no or low protein expression and the presence of aborted translation products. Previously, the typical remedies for overcoming codon bias were to alter the codon specifications of a target gene by site-directed mutagenesis or to circumvent the problem by switching to a eukaryotic expression system.

To make it easier to resolve the codon bias problem, Stratagene released BL21-CodonPlus-RIL competent cells,5 which are derivatives of the BL21-Gold series. BL21-CodonPlus-RIL cells contain a ColE1-compatible vector with extra copies of the argU, ileY, and leuW tRNA genes. These tRNAs recognize arginine, isoleucine, and leucine codons (AGA/AGG, AUA, and CUA), respectively. Host cell expression of these tRNAs can lead to increased synthesis of recombinant proteins, as translation is no longer limited by the availability of tRNAs that recognize rare codons. However, using these codons is predominantly a problem in organisms with AT-rich genomes (Table 1). For organisms whose genomes are GC rich, the problematic codons for expression are the arginine codon AGG (recognized by the tRNA product of the argU gene) and the proline codon CCC (recognized by the tRNA product of the proL gene).

Hence, Stratagene designed BL21-CodonPlus-RP and BL21-CodonPlus(DE3)-RP competent cells to solve this dilemma. These cells include a ColE1-compatible expression plasmid that contains the tRNA genes argU and proL. The corresponding tRNAs recognize the arginine codons, AGA/AGG, and the proline codon, CCC, respectively.

Rare Codons and Protein Production

Fig.1

We per
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. An Epitope Tagging Vector for Gene Expression in Mammalian Cells
2. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
3. Cell Proliferation Kit Outperforms the Competition in the Range of Cells Typically Counted
4. XL10-Gold Cells Supplied in New Single-Reaction Format
5. Isolate and Analyze Total RNA from Cells Harvested by Laser Capture Microdissection
6. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
7. Simple Isolation of RNA from Tissue and Cultured Cells
8. TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins
9. Tools for Detecting MSH2 Expression in Chinese Hamster Ovary Cells
10. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
11. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New CodonPlus Cells Correct Codon Bias Rich Genomes

(Date:11/6/2009)...ire/ -- Calbiotech, Inc. announced today that it h...ch (SBIR) Phase I contract by the U.S. Army Medica...e agreement, Calbiotech will develop analyte speci...rus. ,, Dengue virus is a mosquito-born flav...forces deployed to tropical areas of the world. Du...
(Date:11/5/2009)...FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today ...ter ended September 30, 2009. GenVec reported a ne...hree months ended September 30, 2009 compared to a... comparable quarter of 2008. For the nine months e....1 million ($0.15 per share), compared to a net lo...
(Date:11/5/2009)...5, 2009 at 4:30 p.m. Eastern Time , BOTHELL, ...ncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the...ted financial results for the third quarter and ni...e Company,s highlights for the third quarter of 20...ct the operations of OncoGenex Technologies Inc. (...
(Date:11/5/2009)...swire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX )...eptor-based technologies to discover novel flavor ... supply industries, today provided a corporate upd...uarter ended September 30, 2009. Revenues were $4... to $4.0 million for the third quarter of 2008, an...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...on , , MOUNT LAUREL, N.J. March 23 The ninth a...he premier educational event in the field of basic..., sponsored by the American Society of Transplant ...ansplantation (AST), will occur from May 30 - June... Boston, MA. , , Controversial topics and impor...
...ticals, Inc. (Nasdaq: ARNA ) announced today it ...to $50 million from Azimuth Opportunity Ltd. Durin...ment, Arena may sell newly issued registered share...at a pre-negotiated discount to the market price. ...timing and amount of any sales of its stock, subje...
..., Inc. (CTI) (NASDAQ and MTA: CTIC) today announce... for the year ended December 31, 2008. This filing...CellTherapeutics.com , or on the Securities and Ex..., As required under NASDAQ Marketplace Rule 4350(b...uditor,s report included in the annual report on F...
Other Biology Technology:American Transplant Congress 2009 2Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million 2
(Date:11/5/2009)...esearchers at Yale University have developed synth...une response to HIV and HIV-infected cells, as wel...lished online in the Journal of the American Chem...roaches for these diseases. , The molecules ca...(ARM-H) and "antibody-recruiting molecule targetin...
(Date:11/4/2009)...ridors in the cities of Long Beach and Riverside a...ventable childhood asthma, and the true impact of ...s likely been underestimated, according to researc...). , The study, which appears in an online edit...timated that nine percent of all childhood asthma ...
(Date:11/4/2009)... Oklahoma at Norman has received more than $10 mil... as part of the federal stimulus program, bringing...U researchers to $23 million. Thirty-three projec...rom archaeology to weather. , "The university ha... matching areasof scholarly excellence to federal ...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2USC study finds big air pollution impacts on local communities 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3TransTech Services Partners Inc Shareholders Approve Plan of Liquidation 3B Company To Distribute Amounts in Trust 12971 1TransTech Services Partners Inc Shareholders Approve Plan of Liquidation 3B Company To Distribute Amounts in Trust 12971 2Caraco Pharmaceutical Laboratories Ltd Enters Into Asset Purchase Agreement with Forest Laboratories Inc to Settle Lexapro 28R 29 28escitalopram 51327 1Caraco Pharmaceutical Laboratories Ltd Enters Into Asset Purchase Agreement with Forest Laboratories Inc to Settle Lexapro 28R 29 28escitalopram 51327 2Telomeres resemble DNA fragile sites 9204 1Telomeres resemble DNA fragile sites 9204 2
...ting Initiative (GVFI), a nonprofit research initi...ved $11 million dollars from Google.org and The Sk...illion dollars from each organization, represents ..., an organization whose mission it is to prevent f...ed, brings together fieldwork in disease hotspots ...
...elp Meet Federal Meal Reimbursement ...TOWN, Pa., Oct. 20 ,BIO-key International, Inc. (O... biometric identification and wireless public safe...ng biometric finger scanning ID,for schools, annou...ometric,finger scanning identity solution that qui...
...predominant form of mercury found in the blood of ...be more damaging to seals than has previously been...pen access journal Environmental Health shows th... immune system. Similar results were also found fo...to occur as a result of man-made pollution and nat...
Other Biology News:Global Viral Forecasting Initiative receives $11M to implement pandemic early warning system 2identiMetrics & BIO-key(R) Provide Biometric Finger Scanning for School Food Service Nationwide 2identiMetrics & BIO-key(R) Provide Biometric Finger Scanning for School Food Service Nationwide 3identiMetrics & BIO-key(R) Provide Biometric Finger Scanning for School Food Service Nationwide 4
...ides an extremely fast and efficient single step m...other systems that require tedious optimization or...vantage of the highly selective StrepTactin Superf...siological conditions with low background. With th...
Dr. P Set - Monkey (Cynomolgus) Normal Tissue: Small Intestine from BioChain
Supercoiled DNA Ladder from Invitrogen
Rabbit Anti-CREB-2 (H-290) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: